Baseline demographics and initial treatments at the time of diagnosis of NLPHL in 222 patients
| Variable . | Number (%) . |
|---|---|
| Median age, y (range) | 40 (15-81) |
| Sex (male) | 146 (66) |
| Median follow-up, y (range) | 16 (1.0-42.8) |
| Splenic involvement (data available on 182 patients) | 13 (7) |
| Bone marrow involvement (data available on 180 patients) | 3 (2) |
| Stage | |
| I/II | 166 (75) |
| III/IV | 56 (25) |
| Treatments at the initial diagnosis of NLPHL limited stage (166 patients) | |
| Observation | 4 (2) |
| RT | 116 (70) |
| Chemoradiation (29 patients, 17%) | |
| RT + ABVD | 16 (55.2) |
| RT + R-ABVD | 5 (17.2) |
| RT + MOPP | 4 (13.8) |
| RT + MOPP/ABVD | 2 (6.9) |
| RT + Others | 2 (6.9) |
| Chemotherapy (17 patients, 10%) | |
| ABVD | 7 (41.2) |
| R-ABVD | 2 (11.8) |
| MOPP | 1 (5.9) |
| MOPP/ABVD | 3 (17.6) |
| Others | 4 (23.5) |
| Treatments at the initial diagnosis of NLPHL advanced stage (56 patients) | |
| Observation | 4 (7) |
| RT | 14 (25) |
| Chemoradiation (3 patients, 5%) | |
| RT+ ABVD | 2 (67) |
| RT+ R-ABVD | 1 (33) |
| Chemotherapy (35 patients, 63%) | |
| ABVD | 17 (48.6) |
| R-ABVD | 2 (5.7) |
| MOPP | 3 (8.6) |
| MOPP/ABVD | 5 (14.3) |
| BCVPP | 4 (11.4) |
| Others | 4 (11.4) |
| Variable . | Number (%) . |
|---|---|
| Median age, y (range) | 40 (15-81) |
| Sex (male) | 146 (66) |
| Median follow-up, y (range) | 16 (1.0-42.8) |
| Splenic involvement (data available on 182 patients) | 13 (7) |
| Bone marrow involvement (data available on 180 patients) | 3 (2) |
| Stage | |
| I/II | 166 (75) |
| III/IV | 56 (25) |
| Treatments at the initial diagnosis of NLPHL limited stage (166 patients) | |
| Observation | 4 (2) |
| RT | 116 (70) |
| Chemoradiation (29 patients, 17%) | |
| RT + ABVD | 16 (55.2) |
| RT + R-ABVD | 5 (17.2) |
| RT + MOPP | 4 (13.8) |
| RT + MOPP/ABVD | 2 (6.9) |
| RT + Others | 2 (6.9) |
| Chemotherapy (17 patients, 10%) | |
| ABVD | 7 (41.2) |
| R-ABVD | 2 (11.8) |
| MOPP | 1 (5.9) |
| MOPP/ABVD | 3 (17.6) |
| Others | 4 (23.5) |
| Treatments at the initial diagnosis of NLPHL advanced stage (56 patients) | |
| Observation | 4 (7) |
| RT | 14 (25) |
| Chemoradiation (3 patients, 5%) | |
| RT+ ABVD | 2 (67) |
| RT+ R-ABVD | 1 (33) |
| Chemotherapy (35 patients, 63%) | |
| ABVD | 17 (48.6) |
| R-ABVD | 2 (5.7) |
| MOPP | 3 (8.6) |
| MOPP/ABVD | 5 (14.3) |
| BCVPP | 4 (11.4) |
| Others | 4 (11.4) |
ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; BCVPP: BCNU, cyclophosphamide, vincristine, prednisone and procarbazine; MOPP: mustargen, oncovin, procarbazine, prednisone; NLPHL: nodular lymphocyte predominant Hodgkin lymphoma; R-ABVD: rituximab plus ABVD; RT: radiation therapy.